Latest News and Press Releases

– First patient in Phase 1 clinical trial expected to be treated in Q2 2024 – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – – SENTI-202 is a...

– IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 – – Established new strategic collaboration with Celest Therapeutics for...

– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 2024 – – Senti Bio eligible to receive up to $156 million in...

– Two poster presentations highlighting new preclinical data with BlueRock Therapeutics – – Two poster presentations showcasing Senti Bio’s proprietary Gene Circuit platform – SOUTH SAN FRANCISCO,...

- Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies - - Abstracts include new preclinical data...

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies...

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies...

– GeneFab transaction provides access to clinical manufacturing and extends cash runway into Q4 2024 – – IND for SENTI-202, potentially the first Logic Gated CAR-NK treatment for AML, on...

– Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies – – Transaction anticipated...

SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...